Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Complement System01:27

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HMGN2 deficiency drives DLBCL progression through impaired R-loop formation and PI3K-AKT hyperactivation.

Journal of translational medicine·2026
Same author

Brentuximab vedotin therapy followed by autologous peripheral stem cell transplantation as a viable treatment option for an older adult with transformed lymphoma: a case report and literature review.

The Journal of international medical research·2024
See all related articles

Related Experiment Video

Updated: Jul 2, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Beyond Terminal Blockade: A Mechanism-Based Approach to Complement Inhibitor Selection in Paroxysmal Nocturnal

Chang Chen1, Jinman Zhong1, Dan Xiong1

  • 1Department of Hematology, The Eighth Affiliated Hospital, Southern Medical University (The First People's Hospital of Shunde, Foshan), Foshan, Guangdong, 528300, People's Republic of China.

Drug Design, Development and Therapy
|July 1, 2026
PubMed
Summary
This summary is machine-generated.

Selecting complement inhibitors for paroxysmal nocturnal hemoglobinuria (PNH) requires nuanced assessment. Terminal C5 inhibitors remain primary for thrombosis risk, while proximal inhibitors target specific anemia mechanisms, necessitating a phenotype-driven management strategy.

Keywords:
breakthrough hemolysiscomplement inhibitorsextravascular hemolysisparoxysmal nocturnal hemoglobinuriaphenotype-driven treatment

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Related Experiment Videos

Last Updated: Jul 2, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Area of Science:

  • Hematology
  • Immunology
  • Pharmacology

Background:

  • Paroxysmal nocturnal hemoglobinuria (PNH) treatment selection is complex, moving beyond a simple C5 inhibitor decision.
  • Terminal C5 inhibitors offer robust intravascular hemolysis (IVH) control and proven thromboembolic risk reduction.
  • Persistent anemia under C5 inhibition can stem from incomplete IVH suppression, extravascular hemolysis (EVH), or bone marrow failure (BMF).

Purpose of the Study:

  • To propose a phenotype-driven longitudinal management strategy for PNH treatment.
  • To guide clinicians in differentiating PNH disease mechanisms for optimized inhibitor selection.
  • To address the evidence asymmetry between terminal and proximal complement inhibitors regarding thrombosis prevention.

Main Methods:

  • Review of current evidence on complement inhibitors in PNH.
  • Analysis of diagnostic approaches to differentiate PNH phenotypes (EVH-dominant, BMF-dominant, overlap).
  • Comparative assessment of terminal (C5) and proximal (C3, Factor B, Factor D) complement inhibitors.

Main Results:

  • Terminal C5 inhibitors are crucial for high thrombotic risk and established venous thromboembolism.
  • Persistent anemia requires confirmation of adequate C5 inhibition before attributing to EVH or BMF.
  • Proximal inhibitors target EVH-driven anemia but lack thrombosis prevention trial data, creating an evidence gap.

Conclusions:

  • A phenotype-driven approach is essential for PNH management, considering disease mechanism and thrombotic risk.
  • Differentiating EVH, BMF, and overlap phenotypes is critical for escalating complement inhibitor therapy.
  • Clinical reasoning is paramount when selecting proximal inhibitors due to limited thrombosis data compared to C5 inhibitors.